<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282434</url>
  </required_header>
  <id_info>
    <org_study_id>CLEOPAHTRA</org_study_id>
    <secondary_id>PRIN2017F8ZB89</secondary_id>
    <nct_id>NCT04282434</nct_id>
  </id_info>
  <brief_title>DNA Methylation Dynamics Underlying Arterial Remodeling in PAH Patients: CLEOPAHTRA Clinical Trial</brief_title>
  <acronym>CLEOPAHTRA</acronym>
  <official_title>CLinical Epigenetic-sensitive trajectOries Underlying Pulmonary Arterial Hypertension and neTwoRk Analysis (CLEOPAHTRA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify epigenetic-sensitive modifications and novel biomarkers linked to pathogenesis of&#xD;
      pulmonary arterial hypertension (PAH), we will perform the first study analyzing&#xD;
      differentially-methylated regions (DMRs) in circulating T cells (CD04+ and CD08+) isolated&#xD;
      from peripheral blood of patients undergoing right heart catheterization. Moreover, we will&#xD;
      perform RNA deep sequencing on lung tissue biopsies to validate if DNA methylation signatures&#xD;
      in circulating T cells could reflect perturbations of gene expression in lung tissues.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension (PAH) is characterized by remodeling of pulmonary arteries&#xD;
      caused by an inbalance of proliferation/apoptosis rate within the vascular wall. This&#xD;
      pathological phenotype seems to be triggered by different environmental stress and injury&#xD;
      events such as increased inflammation, DNA damage, and epigenetic deregulation. Many immune&#xD;
      cells are increased in PAH, such as T and B lymphocytes. Remarkably, T cells are essential&#xD;
      players of adaptive immunity and may be relevant initiators (&quot;initial hit&quot;) of vascular&#xD;
      remodelling. We will perform the first multi-omics study to: 1) investigate DNA methylome of&#xD;
      circulating T cells isolated from peripheral blood of PAH patients, 2) detect transcriptomic&#xD;
      profiles of lung tissues, 3) to assess if DNA methylation of distinct genomic regions in&#xD;
      circulating T cells could reflect modifications of lung gene expression programs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Actual">October 14, 2020</completion_date>
  <primary_completion_date type="Actual">June 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of differentially methylated regions in CD04 and CD08 T cells</measure>
    <time_frame>3 Months</time_frame>
    <description>Reduced Representation Bisulfite Sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of differentially expressed genes in lung tissue biopsies</measure>
    <time_frame>5 Months</time_frame>
    <description>Chip Microarray</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioinformatic analysis</measure>
    <time_frame>8 Months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Pulmonary Arterial Remodeling</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Circulating T cells Lung tissue biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        30 PAH patients (familial and idiopathic) vs 30 sex and age-matched subjects.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed patients with World Health Organization (WHO) Group I PAH.&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  Documentation of the following hemodynamic parameters by right heart catheterization,&#xD;
             performed at time of study enrolment:&#xD;
&#xD;
          -  Mean pulmonary arterial pressure (mPAP) &gt; 25 mmHg at rest or mPAP &gt; 30 mm Hg with&#xD;
             exercise.&#xD;
&#xD;
          -  Pulmonary arterial wedge pressure (PAWP) ≤ 15 mm Hg.&#xD;
&#xD;
          -  Pulmonary vascular resistance (PVR) ≥ 240 dynes.sec.cm-5 (e.g., ≥ 3.0 Wood units)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who meet the criteria for inclusion into WHO Groups II, III, IV or V.&#xD;
&#xD;
          -  Do not meet the required hemodynamic criteria for entry into the study.&#xD;
&#xD;
          -  Patients with known history of cancer, malignancy disorders, active infections, and&#xD;
             chronic or immune-mediated diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Giuditta Benincasa, BiolD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;L. Vanvitelli&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monaldi Hospital</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Napoli C, Benincasa G, Loscalzo J. Epigenetic Inheritance Underlying Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):653-664. doi: 10.1161/ATVBAHA.118.312262. Review.</citation>
    <PMID>30727752</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Giuditta Benincasa</investigator_full_name>
    <investigator_title>Principal Investigator Giuditta Benincasa</investigator_title>
  </responsible_party>
  <keyword>Adaptive immunity</keyword>
  <keyword>DNA methylome</keyword>
  <keyword>RNA-sequencing</keyword>
  <keyword>Network analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Vascular Remodeling</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

